Azithromycin Dihydrate

Licensed by Pfizer Catalog No.S4147

For research use only.

Azithromycin Dihydrate is an acid stable orally administered macrolide antimicrobial drug, structurally related to erythromycin.

Azithromycin Dihydrate Chemical Structure

CAS No. 117772-70-0

Selleck's Azithromycin Dihydrate has been cited by 7 Publications

Purity & Quality Control

Choose Selective Anti-infection Inhibitors

Biological Activity

Description Azithromycin Dihydrate is an acid stable orally administered macrolide antimicrobial drug, structurally related to erythromycin.
In vitro

Azithromycin displays a similar spectrum of antimicrobial activity. Azithromycin is marginally less active than erythromycin in vitro against Gram-positive organisms, although this is of doubtful clinical significance as susceptibility concentration fall within the range of achievable tissue Azithromycin concentrations. The mean MIC90 of Azithromycin against erythromycin susceptible/βL-ve strains, Streptococcus strains and NS (not selected for antimicrobial sesitivity)/erythromycin susceptible strains is 0.63, 0.35, and <0.27 mg/L, respectively. In contrast, Azithromycin appears to be more active than erythromycin against many Gram-negative pathogens and several other pathogens, notably Haemophilus influenza (MIC90, 1.34 mg/L), H. parainfluenzae(MIC90, 1 mg/L), Moraxella catarrhalis (MIC90, <0.1 mg/L), Neisseria gonorrhoeae (MIC90, 0.25 mg/L), Ureaplasma urealyticum, Bordetella spp (MIC90, 0.03-0.24 mg/L) and Borrelia burgdorferi. Azithromycin is also activity against clinical isolates of anaerobic bacteria Gram-positive cocci and propionibacterium acnes with MIC90 of 2.3, 0.03 mg/L. Like erythromycin and other macromycin, the activity of Azithromycin is unaffected by the production of β-lactamase. However, erythromycin-resistant organisms are also resistant to Azithromycin. [1]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 785.02


CAS No. 117772-70-0
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O.O.O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05398055 Recruiting Drug: Azithromycin + Doxycycline|Drug: Placebo + Doxycycline Rocky Mountain Spotted Fever Hospital General de Mexicali May 12 2022 Phase 3
NCT05465304 Completed Drug: Azithromycin Pregnant With Complication Beni-Suef University October 1 2021 --
NCT04326478 Recruiting Drug: Azithromycin|Biological: Placebo Cholera Massachusetts General Hospital|International Centre for Diarrhoeal Disease Research Bangladesh October 31 2021 Phase 2
NCT04669288 Recruiting Drug: Azithromycin|Drug: Placebo Asthma|Wheezing University of Arizona|University of Utah|Emory University|Morgan Stanley Children''s Hospital|University of Pittsburgh|Children''s Hospital and Health System Foundation Wisconsin|Children''s Hospital of Philadelphia|Children''s Hospital Medical Center Cincinnati|Boston Children''s Hospital September 22 2021 Phase 3
NCT04617626 Completed Drug: Azithromycin Child Mortality|Azithromycin FHI 360|National Program for the Fight Against Neglected Tropical Diseases Côte d''Ivoire November 20 2020 Not Applicable

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Azithromycin Dihydrate | Azithromycin Dihydrate ic50 | Azithromycin Dihydrate price | Azithromycin Dihydrate cost | Azithromycin Dihydrate solubility dmso | Azithromycin Dihydrate purchase | Azithromycin Dihydrate manufacturer | Azithromycin Dihydrate research buy | Azithromycin Dihydrate order | Azithromycin Dihydrate mouse | Azithromycin Dihydrate chemical structure | Azithromycin Dihydrate mw | Azithromycin Dihydrate molecular weight | Azithromycin Dihydrate datasheet | Azithromycin Dihydrate supplier | Azithromycin Dihydrate in vitro | Azithromycin Dihydrate cell line | Azithromycin Dihydrate concentration | Azithromycin Dihydrate nmr